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proteomics-based functional 
studies reveal that galectin-3 
plays a protective role in the 
pathogenesis of intestinal Behçet’s 
disease
Hyun Jung Lee1,2, Jae Hyeon Kim  1,3, Sujeong Hong4, Inhwa Hwang4, Soo Jung park  1, 
tae il Kim  1, Won Ho Kim1, Je-Wook Yu4, Seung Won Kim1,3,5 & Jae Hee cheon1,3,5
The pathogenesis of intestinal Behçet’s disease (BD) remains poorly understood. Therefore, we aimed 
to discover and validate biomarkers using proteomics analysis and subsequent functional studies. 
After two-dimensional electrophoresis, candidate proteins were identified using matrix-assisted laser 
desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS). We validated 
these results by evaluating the protein levels and their functions in vitro using HT-29 colorectal cancer 
cells, colon tissues from patients and mice, and murine bone marrow derived macrophages (BMDMs). 
Of the 30 proteins differentially expressed in intestinal BD tissues, we identified seven using MALDI-
TOF/TOF MS. Focusing on galectin-3, we found that TGF-B and IL-10 expression was significantly 
lower in shLGALS3-transfected cells. Expression of GRP78 and XBP1s and apoptosis rates were all 
higher in shLGALS3-transfected cells upon the induction of endoplasmic reticulum stress. In response 
to lipopolysaccharide stimulation, microtubule-associated protein 1 light chain 3B accumulated and 
lysosomes decreased in these cells. Finally, Salmonella typhimurium infection induced caspase-1 
activation and increased IL-1β production, which facilitated activation of the NLRC4 inflammasome, 
in Lgals3−/− murine BMDMs compared to wild type BMDMs. Our data suggest that galectin-3 may 
play a protective role in the pathogenesis of intestinal BD via modulation of ER stress, autophagy, and 
inflammasome activation.
Intestinal Behçet’s disease (BD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract; the 
diagnosis of this disease is typically based on colonoscopic features and clinical manifestations1. The incidence 
of intestinal BD is higher in East Asian countries, including Korea and Japan, compared to the Middle Eastern 
countries2. Intestinal BD has an unpredictable disease course with exacerbation and remission, and often requires 
surgical treatment due to massive bleeding, fistula, or bowel perforation3,4. Because the surgery rates for intesti-
nal BD are comparable to those for Crohn’s disease (CD) due to high rates of complications5, better methods for 
diagnosis and management of intestinal BD are needed. A better understanding of the pathogenesis of intestinal 
BD would be invaluable.
Both genetic and environmental factors contribute to inflammatory bowel disease (IBD) etiology. A grow-
ing body of evidence demonstrates that epithelial barrier defects and dysregulated mucosal immune responses 
to intestinal microbes in genetically susceptible individuals might result in sustained intestinal inflammation6. 
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Dysregulated enterocyte shedding and apoptosis is known to cause intestinal barrier instability7 and inappro-
priate innate immune responses to commensal flora and defective autophagy function are observed in patients 
with IBD8,9. To date, genome-wide association studies (GWAS) have revealed more than 200 genetic biomarkers 
for the development of IBD, including CARD15/NOD2, ATG16L1, and IRGM8–11. In general, intestinal BD has 
similar clinical and therapeutic characteristics to IBD. However, although we recently identified several genetic 
loci (IL17A, IL23R, STAT4, NAALADL2, and YIPF7) associated with susceptibility to intestinal BD12,13, relatively 
little is known about the disease pathogenesis of intestinal BD, highlighting the need for further study to aid in 
the diagnosis and treatment of this disease.
In recent decades, because of the limitations of currently available biomarkers, proteomics is gaining popular-
ity for biomarker discovery in IBD. These approaches have proven particularly useful for the identification of IBD 
biomarkers, aiding in diagnosis, measurement of disease activity, and the prediction of treatment response14–16. 
In contrast, to the best of our knowledge, a proteomics approach to identify biomarkers in intestinal BD has not 
yet been described. Therefore, we aimed to find biomarkers associated with intestinal BD pathogenesis using 
two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS)-based proteomics. Furthermore, we 
sought to elucidate the pathogenic mechanisms of a single candidate protein using various in vitro functional 
studies. Our work, for the first time, describes the proteomics approaches as useful techniques for identifying 
biomarkers associated with intestinal BD and reports a previously undescribed association between the disease 
and the galectin-3 (Gal-3) protein, suggesting a potential significance of this protein in the pathogenesis of intes-
tinal BD.
Methods
Human subject demographics and sample collection. A total of 17 patients diagnosed with intestinal 
BD and 17 non-affected control individuals were enrolled in this study at Severance Hospital, Yonsei University, 
in Seoul, Korea. Intestinal BD diagnosis was made according to previously established criteria based on colono-
scopic features and clinical manifestations using a modified Delphi process1. Tissue samples were obtained from 
both inflamed and non-inflamed intestinal tissues of intestinal BD patients undergoing surgery due to bowel 
complications and/or intractability to medical treatments. Control samples were obtained from normal intestinal 
tissues from subjects undergoing colorectal surgery for colorectal cancer, malignant bowel obstruction due to 
stomach cancer, or appendiceal mucocele. Samples were immediately frozen in liquid nitrogen and subsequently 
stored at −80 °C until preparation for proteomic analyses.
Informed consent was obtained from all individuals enrolled in this study. This study was approved by the 
Institutional Review Boards of Yonsei University College of Medicine (IRB approval number: 4-2012-0680) and 
was conducted in accordance with the Declaration of Helsinki.
Two-dimensional electrophoresis (2-DE). Two-dimensional electrophoresis (2-DE) was carried out 
essentially as described17,18. Aliquots in sample buffer (7 M urea, 2 M thiourea, 4.5% CHAPS, 100 mM DTT, 
40 mM Tris, pH 8.8) were applied to immobilized pH 3–10 nonlinear gradient strips (Amersham Biosciences, 
Uppsala, Sweden). Isoelectric focusing (IEF) was performed at 80,000 Vh. The second dimension was analyzed 
on 9–16% linear gradient polyacrylamide gels (18 cm × 20 cm × 1.5 mm) at a constant 40 mA per gel for approx-
imately 5 h. After protein fixation in 40% methanol and 5% phosphoric acid for 1 h, the gels were stained with 
Coomassie G-250 solution for 12 h. The gels were destained with H2O, scanned in a Bio-Rad GS710 densitometer 
(Life Science, Richmond, CA, USA) and converted into electronic files, which were then analyzed with Image 
Master Platinum 5.0 (Amersham Biosciences).
Protein identification by MALDI‒TOF/TOF MS. Protein spots were excised from the gels with a sterile 
scalpel and placed into Eppendorf tubes. Proteins were digested using trypsin (Promega, Madison, WI, USA) 
as previously described17,19. For matrix-assisted laser desorption/ionization tandem time-of-flight mass spec-
trometry (MALDI‒TOF/TOF MS) analysis, the tryptic peptides were concentrated by a POROS R2, Oligo R3 
column (Applied Biosystems, Foster City, CA, USA). After washing the column with 70% acetonitrile, 100% 
acetonitrile and then 50 mM ammonium bicarbonate, samples were applied to the R2, R3 column and eluted with 
cyano-4-hydroxycinamic acid (CHCA) (Sigma-Aldrich, St. Louis, MO, USA), and then dissolved in 70% ace-
tonitrile and 0.1% TFA before MALDI-TOF/TOF MS analysis. Mass spectra were acquired on a 4800 Proteomics 
Analyzer (Applied Biosystems) operated in MS and MS/MS modes. Peptide fragmentation in MS/MS mode was 
by collision-induced dissociation (CID) using atmosphere as the collision gas. The instrument was operated in 
reflectron mode and calibrated using the 4700 calibration mixture (Applied Biosystems) and each sample spec-
trum was additionally calibrated using trypsin autolysis peaks. For MS analysis, a 800–4000 m/z mass range was 
used with 1000 shots per spectrum. A maximum of 15 precursors with a minimum S/N of 50 were selected for 
MS/MS analysis. Collision energy of 1 kV was used for CID, and 2000 acquisitions were accumulated for each 
MS/MS spectrum. Peptide mass fingerprinting was carried out using the Mascot search engine included in the 
GPS Explorer software and mass spectra used for manual de novo sequencing were annotated with the Data 
Explorer software (Applied Biosystems).
Mascot database search. The mascot algorithm (Matrixscience, Boston, MA, USA) was used to identify 
peptide sequences present in a protein sequence database as previously described17. Database search criteria 
were, taxonomy; homo sapiens (NCBInr database downloaded on Mar 24 2013), fixed modification; carboxyam-
idomethylated (+57) at cysteine residues; variable modification; oxidized (+16) at methionine residues, maxi-
mum allowed missed cleavage, 1. Mass tolerances of 100 ppm, 0.1 Da were used for precursor and fragment ions, 
respectively. Only peptides resulting from trypsin digests were used for protein identification.
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Immunohistochemical staining of colon tissues to verify 2-DE and MALDI-TOF results. We 
performed immunohistochemistry (IHC) staining on tissue sections to quantify Gal-3 levels using a Vecastain 
ABC kit (Vector Labs, Burlingame, CA, USA). Tissue sections were incubated first with the primary anti-Gal-3 
antibody (1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4 °C, followed by incubation 
with a biotinylated secondary linking antibody for 1 h, and finally for 1 h with a streptavidin-peroxidase complex. 
The final color product was developed using aminoethylcarbazole (Dako, Carpinteria, CA, USA). Sections were 
counterstained with hematoxylin and mounted, and the tissues were photographed using an Olympus photomi-
croscope (Olympus Corp., Tokyo, Japan). For quantitative analysis, we randomly selected 4 fields for each sample 
at 200× magnification and scored the ratios of positively Gal-3 stained cells to all cells. The percentage of positive 
cells and the intensity of staining were scored from 0 to 3 (0 =< 10%, 1 = 10–50%, 2 = 50–75%, 3 = 75–100%) as 
previously described20.
Western blotting. Proteins were extracted from colon tissues or HT-29 cells and were lysed and homoge-
nized in a buffer containing 50 mM Tris-Cl at pH 8.0, 150 mM NaCl, 0.1% SDS, 1 mM EDTA, 1% Triton‒X, 0.05% 
sodium deoxycholate, and protease inhibitors. Protein samples were fractionated on 12% SDS-PAGE and trans-
ferred onto polyvinylidene difluoride (PVDF) membranes for 70 min at 100 volts (Bio-Rad). Blots were incubated 
with primary anti-Gal-3 antibody (1:2000, sc-20157, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 
anti-caspase-1 antibody (1:2000, Santa Cruz), anti-GRP78 antibody (1:2000, ABCAM, Cambridge, MA, USA), 
anti-XBP-1 antibody (1:2000, NOVUS BIO, Littleton, CO, USA), and anti-IL-1β antibody (1:2000, R&D system, 
MN, USA) followed by horseradish peroxidase-conjugated secondary antibody and enhanced chemilumines-
cence (ECL) reagents using the ECL kit (Thermo Scientific, MA, USA). Anti-β-actin (Santa Cruz Biotechnology) 
was used as the loading control.
Quantitative real-time reverse-transcription polymerase chain reaction (qRt-pcR). Total RNA 
extraction and reverse-transcription was performed as previously described17,21. PCR primer information is 
described in Supplementary Table 1. Samples were amplified in a StepOne Plus real-time PCR system (Applied 
Biosystems) for 45–55 cycles using the following cycling conditions: 95 °C for 15 sec, 60–63 °C for 30 sec, and 
72 °C for 40 sec. Quantitative analysis was performed using the relative standard curve, and the results were 
reported as a relative expression or fold change compared to the calibrator after normalization of the transcript 
level against control, β-ACTIN.
Transfection and treatment of HT-29 cells. We maintained the HT-29 colon cancer cell line (KCLB 
30038, Korean Cell Line Bank, Seoul, Korea) at 37 °C in Roswell Park Memorial Institute medium (RPMI 
medium) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotics in a humidi-
fied atmosphere of 5% CO2. We transfected HT-29 cells with human Gal-3 small hairpin RNA (shRNA, Santa 
Cruz Biotechnology) plasmids to create Gal-3 knock-down cell lines using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA). Control cells with transfected with scrambled shRNA. Successfully transfected cells were 
isolated by selection with 20 μg/ml puromycin (Santa Cruz Biotechnology) for 4 weeks. After purification of 
Puromycin-resistant cell lines, Gal-3 expression was evaluated using Western blot analysis. Subsequently, sta-
ble Gal-3-silenced cell lines (shLGALS3) and control cell lines (SCR, scramble) were selected for further anal-
ysis. Cells were incubated with TNF-α (40 ng/mL, R&D systems) and lipopolysaccharide (LPS, 1–10 μg/mL, 
Sigma-Aldrich) with or without recombinant human Gal-3 (10 μM, Prospec, NJ, USA) for 4 h (qRT-PCR) or 24 h 
(western blot).
Immunofluorescence staining to quantify Gal-3 and LC3B protein levels and trace lysosomes in 
transfected HT-29 cells. To quantify Gal-3 protein levels in shLGALS3 transfected and control HT-29 cells 
we performed immunofluorescence staining as follows: First, cells were fixed with a 4% paraformaldehyde solu-
tion (pH 7.4). After a PBS wash, cells were blocked in 5% BSA with 0.1% Triton X-100, washed with PBS again, 
and incubated with primary antibodies (anti-microtubule-associated protein 1 light chain‒3B (LC3B), 1:1,000; 
anti-Gal-3, 1:500). Primary antibodies were fluorescently labeled with Alexa Fluor 488- and 633-conjugated sec-
ondary antibodies (1:500). Cell nuclei were stained with DAPI solution. For tracing lysosomal fusion with auto-
phagosomes, cells were incubated with LysoTracker® Red DND-99 (100 nM, Molecular Probes, Eugene, OR, 
USA). Images were obtained via fluorescence microscopy (Olympus BX41; Olympus Optical, Tokyo, Japan) at a 
magnification of 400× or confocal microscopy (Carl Zeiss LSM 700, Prenzlauer, Berlin, Germany) at a magnifi-
cation of 800×.
Quantification of apoptosis in shLGALS3-transfected HT-29 cells via flow cytometry. Apoptosis 
in transfected HT-29 cells were quantified via flow cytometry using an Annexin V-FITC/PI kit (BD Biosciences, 
San Diego, CA, USA). A total of 30,000 events were collected from each sample using a FACSverse flow cytome-
ter (BD Biosciences), and the resulting spectra were analyzed using Flow Jo software (Tree Star, San Carlos, CA, 
USA).
Isolation of bone marrow-derived murine macrophages. Murine primary bone marrow-derived 
macrophages (BMDMs) were prepared from C57BL/6 mice as described previously22. Bone marrow cells were 
isolated from femurs of C57BL/6 mice and differentiated for one week in L929-conditioned DMEM/F-12 
medium supplemented with 10% FBS. All mice were maintained under specific pathogen-free conditions, and 
all experiments using BMDMs were performed in accordance with the approved guidelines of the Institutional 
Animal Care and Use Committee of Yonsei University Severance Hospital, Seoul, Korea (IACUC, Approval No: 
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2013–0166). All BMDMs were maintained in L929-conditioned DMEM supplemented with 10% FBS and 100 U/
mL penicillin/streptomycin.
Statistical analysis. Data are expressed as mean ± standard deviation (SD) or ± standard error of mean 
(SEM). Parametric and nonparametric analyses were performed using Student’s t-test and Mann-Whitney U test, 
respectively. P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 
V20.0 for Windows (SPSS Inc., Chicago, IL, USA) or Prism software 5 (GraphPad Software, Inc., San Diego, CA, 
USA).
Results
Gal-3 is down-regulated in inflamed intestinal tissue from intestinal BD patients. The clini-
cal characteristics of 17 intestinal BD cases and 17 non-affected controls enrolled in this study are shown in 
Supplementary Table 2.
We first performed a tissue proteomics analysis using 2-DE to identify differentially expressed proteins 
between the case and control groups. Approximately 550 protein spots were observed (Fig. 1), with a total of 30 
protein spots found to have qualitative or quantitative differences in intestinal BD tissues compared to controls. 
Specifically, 12 were up-regulated, 15 were down-regulated, and 3 were observed in the intestinal BD tissues 
alone. We focused on highly differently expressed proteins only; therefore, spots with a 5-fold or higher change 
between case and control tissues and uniquely manifested in either of the two gels were defined as differen-
tial. Seven (four upregulated and three downregulated) of these highly differentially expressed proteins were 
incised from the gels and analyzed by MALDI-TOF/TOF MS for protein identification. The upregulated proteins 
were identified as heat shock protein 27 (2.2-fold), transgelin (4.7-fold), superoxide dismutase (3.3-fold), and 
calprotectin (9.3-fold). The down-regulated proteins were identified as heat shock protein 60 (−7.0-fold), sele-
nium binding protein (−9.0-fold), and Gal-3 (−5.8-fold) (Table 1). These proteins are known to be involved in 
stress response, oxidative stress, and/or inflammation23–25. Interestingly, Gal-3 has been reported as an immune 
response regulator in chronic inflammatory disorders including IBD26–28. Therefore, we focused on Gal-3 for 
further investigations. The typical peptide mass fingerprinting (PMF) and MS/MS spectrum of Gal-3 are shown 
in Supplementary Fig. 1.
We next used IHC staining of the colonic tissues to confirm whether Gal-3 levels are lower in intestinal BD. 
IHC confirmed that Gal-3 levels were significantly reduced in both the inflamed and non-inflamed crypt epithelia 
from intestinal BD patients compared to non-inflamed control tissues (Fig. 2A,B). Therefore, we hypothesized 
that Gal-3 may play a protective role against development of intestinal BD, and that when Gal-3 expression is 
decreased in the inflamed intestinal tissues, an individual is at risk for developing intestinal BD. Taken together, 
these data support our proteomic observation that Gal-3 might play a protective role and be involved in the 
pathogenesis of intestinal BD. When it is down-regulated in the inflamed intestinal mucosa, intestinal BD can 
develop.
Gal-3 knockdown negatively affects anti-inflammatory cytokine expressions in intestinal epi-
thelial cells. Because Gal-3 is a reported immune response regulator, we next determined whether Gal-3 
could affect anti-inflammatory cytokine expression in human HT-29 colorectal cancer cells. We knocked-down 
Figure 1. Proteomic profiles of intestinal tissue from patients with intestinal Behçet’s disease and non-
affected controls. Seven significantly differentially expressed protein fractions (red circles) identified via two-
dimensional electrophoresis (2-DE) were excised and further analyzed by matrix-assisted laser desorption/
ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) (arrows on 2-DE gels). Spot 
number was assigned by image analysis program, followed by 2-DE.
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the LGALS3 gene in HT-29 cells via shRNA transfection (shLGALS3) and established a stable cell line through 
antibiotics selection (Supplementary Fig. 2). We confirmed decreased LGALS3 levels using quantitative RT-PCR 
and Western blotting (Fig. 3A,B and Supplementary Fig. 3A,B, respectively). When the transfected cells were 
treated with LPS to induce an inflammatory response, the expression of anti-inflammatory cytokines TGF-β 
and IL-10 was significantly lower in cells transfected with shLGALS3 compared to scramble-transfected cells 
(Fig. 3C,D), confirming the role of Gal-3 as an immune response regulator in intestinal epithelial cells.
Loss of Gal-3 leads to endoplasmic reticulum stress-induced cell death and induces autophagy 
defects in intestinal epithelial cells. Recent studies have reported that unresolved endoplasmic reticu-
lum (ER) stress and autophagy defects can trigger epithelial cell apoptosis and inflammation29,30, and that these 
defects are linked to impaired barrier function and IBD pathogenesis7. Therefore, we determined whether similar 
defects were present in intestinal epithelial cells lacking Gal-3, which would support a role for Gal-3 in preventing 
intestinal BD-associated autophagy defects and ER stress-associated cell death. We induced ER stress in shL-
GALS3 cells using LPS, thapsigargin, or serum starvation. Expression of the ER and cellular stress-associated 
glucose-regulated protein (GRP78) and spliced XBP1 (XBP1s), an active spliced form of X-box–binding protein 
1, were markedly increased by LPS-stimulation in shLGALS3 cells (Fig. 4A–C and Supplementary Fig. 4A–D). 
Additionally, ER stress by all three conditions was associated with a significantly higher incidence of cell 
death in shLGALS3 cells, and this increased cell death was reversed upon treatment with Gal-3 (Fig. 4D and 
Supplementary Fig. 5A,B).
Spot
no Protein description Accession no Mr(kDa)/pI Matched peptide sequence Fold change
404 60 kDa heat shock protein, mitochondrial gi|129379 61187/5.70
IGIEIIKR(41)
TVIIEQSWGSPK(79)
GYISPYFINTSK(57)
VGEVIVTKDDAMLLK(17)
ISSIQSIVPALEIANAHR(28)
IQEIIEQLDVTTSEYEKEK(37)
KPLVIIAEDVDGEALSTLVLNR(95)
DMAIATGGAVFGEEGLTLNLEDVQPHDLGK(4)
−7.0
503 Selenium binding protein1 gi|14290607 52928/5.93
DGLIPLEIR(41)
LVLPSLISSR(18)
HEIVQTLSLK(87)
IYVVDVGSEPR(51)
QYDISDPQRPR(30)
GGFVLLDGETFEVK(35)
VAGGPQMIQLSLDGKR(32)
HNVMISTEWAAPNVLR(33)
GTWERPGGAAPLGYDFWYQPR(22)
DGFNPADVEAGLYGSHLYVWDWQR(38)
−9.0
890 Galectin-3 gi|2385452 26193/8.57
IALDFQR(35)
FNENNRR(35)
IQVLVEPDHFK(72)
QSVFPFESGKPFK(90)
MLITILGTVKPNANR(26)
LGISGDIDLTSASYTMI(10)
−5.8
950 Heat shock protein 27 gi|11036357 22826/5.98
VPFSLLR(52)
AQLGGPEAAK(37)
DWYPHSR(44)
RVPFSLLR(26)
QLSSGVSEIR(90)
QDEHGYISR(61)
HEERQDEHGYISR(46)
VSLDVNHFAPDELTVK(108)
2.2
1006 Transgelin gi|3123283 22653/8.87
GDPNWFMK(31)
QMEQVAQFLK(25)
VPENPPSMVFK(64)
VPENPPSMVFK(27)
GASQAGMTGYGRPR(20)
LVNSLYPDGSKPVK(79)
TDMFQTVDLFEGK(67)
TDMFQTVDLFEGKDMAAVQR(134)
TDMFQTVDLFEGKDMAAVQR(43)
AAEDYGVIKTDMFQTVDLFEGK(30)
4.7
1014 Superoxidedismutase gi|134665 24878/8.35
NVRPDYLK(41)
GELLEAIKR(58)
DFGSFDKFK(67)
GDVTAQIALQPALK.(103)
LTAASVGVQGSGWGWLGFNK.(155)
HHAAYVNNLNVTEEKYQEALAK(44)
3.3
1188 Protein S100-A8 gi|115442 10885/6.51
MGVAAHKK(14)
GNFHAVYR(60)
GNFHAVYRDDLK(50)
ELDINTDGAVNFQEFLILVIK(60)
9.3
Table 1. Protein identification by MALDI-TOF/TOF. Mr, molecular mass (kDa).
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Figure 2. Galectin‒3 is down-regulated in inflamed intestinal tissues from intestinal Behçet’s disease patients. 
(A,B) Immunohistochemistry of galectin-3. Intestinal tissues from non-affected controls (n = 15) and patients 
with intestinal Behçet’s disease (n = 15) were stained with anti-galectin-3 antibodies and counterstained 
with hematoxylin. Representative images of inflamed and non-inflamed intestinal tissues are shown in (A) at 
200 × magnification. Galectin-3 expression in normal, inflamed, and non-inflamed intestinal tissues is shown 
in (B). Results are shown as individual values (symbols) with the standard deviation indicated (lines) for each 
group of patients. *p < 0.05 vs. HC, ***p < 0.005 vs. HC. HC, healthy control; intBD, intestinal BD.
Figure 3. Loss of galectin-3 affects anti-inflammatory cytokine expression in HT-29 cells. (A) Transcript levels 
of galectin-3 gene (LGALS3). (B) Galectin-3 protein levels. Transcript levels of (C) TGF-B and (D) IL-10. Data 
are presented as the mean ± SD (n = 3). *p < 0.05 vs. SCR, **p < 0.01 vs. SCR, ***p < 0.05 vs. SCR, #p < 0.05 
vs. LPS, ##p < 0.01 vs. LPS. Veh, treated with phosphate-buffered saline; LPS, treated with lipopolysaccharide; 
rhGal3, treated with recombinant human galectin-3; SCR, scramble control HT-29 cell; shLGALS3, HT-29 cell 
stably expressing LGALS3 shRNA.
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Because Gal-3 has been proposed as a marker of lysed vacuole membranes and a target of autophagy31, we 
next investigated the role of Gal-3 in the process of autophagic removal of invasive pathogens. Treatment of 
HT-29 cells with a TLR4 agonist, LPS, led to a significant increase in autophagosomes, as demonstrated by an 
increase in the detection of LC3B, a central protein in the autophagy pathway, within cells by fluorescence micros-
copy. Autophagic cell numbers were increased in abundance among the shLGALS3 cell population in response 
to serum starvation and LPS, as reflected by increased accumulation of LC3B-positive vesicles (punctae, Fig. 5A). 
Additionally, there were more apoptotic bodies in shLGALS3 cells compared to scramble shRNA-transfected 
control cells (Supplementary Fig. 6A). In contrast, phagosomal acidification was lower in shLGALS3 cells upon 
serum starvation and LPS compared to control cells (Fig. 5B and Supplementary Fig. 6B). Notably, LC3B was not 
recruited to Gal-3 puncta, but co-localization of Gal-3 with lysosomes increased in response to serum starvation 
and LPS, which might result in decreased autolysosome formation (Supplementary Fig. 7A–C). Altogether, our 
data suggest that Gal-3 plays a role in lysosomal signaling that is indispensable for a properly functioning auto-
phagic pathway.
Loss of Gal-3 increases inflammasome activity and causes bacteria-induced inflammasome 
activation. Autophagy negatively regulates inflammasome activity32 and accumulating evidence has shown 
that the inflammasome plays a pivotal role in host defense against intestinal microbes and intestinal inflamma-
tion33. Inflammasome activation results in the recruitment and activation of caspase-1, a key enzyme in the pro-
cessing of pro-IL-1β into the mature IL-1β. This finding, together with our previous observations that autophagy 
is defective in cells lacking Gal-3, led us to determine whether NLRP3, NLRC4, and IL-1B transcript levels were 
altered in inflamed colon tissues of intestinal BD patients compared to non-affected control tissues. As shown 
in Fig. 6A, NLRP3 mRNA levels were not significantly different between inflamed and control tissues, whereas 
expression of IL-1B (though statistically not significant) and NLRC4 were higher in inflamed colon tissues 
Figure 4. Loss of galectin-3 activates endoplasmic reticulum (ER) stress and promotes cell death in HT-29 cells. 
(A,B) Expression of ER and cellular stress indicator proteins GRP78 and XBP1s in cells treated with LPS (A,B). 
Transcript levels were quantified by real-time quantitative reverse transcription polymerase chain reaction and 
normalized to β-actin expression levels. (C) Protein levels were quantified by western blotting and normalized 
to β-actin. *p < 0.05 vs. SCR, **p < 0.01 vs. SCR, ***p < 0.05 vs. SCR, #p < 0.05 vs. LPS, ###p < 0.005 vs. LPS. Veh, 
treated with phosphate-buffered saline; LPS, treated with lipopolysaccharide; rhGal3, treated with recombinant 
human galectin-3; SCR, scramble control HT-29 cell; shLGALS3, HT-29 cell expressing stably LGALS3 shRNA. 
(D) Effects of galectin-3 on cell death by ER stress inducer, LPS, were shown through Annexin V/PI staining. 
Data are presented as mean ± SD (n = 3). Veh, treated with phosphate-buffered saline; LPS treated with 
lipopolysaccharide; rhGal3, treated with recombinant human galectin-3 (10 μM); SCR, scramble control HT-29 
cell; shLGALS3, HT-29 cell stably expressing LGALS3 shRNA.
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Figure 5. Loss of galectin-3 induces autophagy defects. Transfected HT-29 cells were treated with LPS 
to induce ER stress and subsequent autophagy. (A) Representative confocal images of autophagosomic 
endogenous LC3B localization. (B) Representative confocal images of lysosomes at 800 × magnification. Red 
color indicates LysoTracker, an indicator of phagosomal acidification. Experiments were performed in triplicate. 
Veh, treated with phosphate-buffered saline; +Ser, 10% serum supplemented; -Ser, serum free; LPS, treated with 
lipopolysaccharide; rhGal3, treated with recombinant human galectin-3 (10 μM); SCR, scramble control HT-29 
cells; shLGALS3, HT-29 cells stably expressing LGALS3 shRNA; DIC, differential interference contrast (DIC).
Figure 6. Galectin-3 affects inflammasomes in the colon tissues from patients with intestinal BD and intestinal 
epithelial cells. (A) mRNA levels in colon tissues. Transcript levels of LGALS3, IL-1B, NLRP3, and NLRC4 from 
human colon tissues were quantified by real-time quantitative reverse transcription polymerase chain reaction 
and normalized to β-actin. (B) Gene expression related to inflammasomes (IL-1B, NLRC4, TLR5) in cells 
treated with rhTNF-α or LPS. Data represent mean ± SD (n = 3). Cells were treated with TNF-α (40 ng/ml) or 
LPS (1 μg/ml) for 4 h in mRNA analysis and for 24 h in protein analysis. The transcript levels were quantified 
by real-time quantitative reverse transcription polymerase chain reaction and normalized to β-actin. *p < 0.05 
vs. HC or SCR, **p < 0.01 vs. HC or SCR, ***p < 0.005 vs. HC or SCR, #p < 0.05 vs. TNF-α, ##p < 0.01 vs. TNF-
α, ###p < 0.005 vs. TNF-α. Veh, treated with phosphate-buffered saline; rhTNF-α, treated with recombinant 
human TNF-α; LPS, treated with lipopolysaccharide; rhGal3, treated with recombinant human galectin-3; SCR, 
scramble control HT-29 cells; shLGALS3, HT-29 cells expressing stably LGALS3 shRNA.
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compared to healthy controls. Consistently, IL-1B, NLRC4, and TLR5 mRNA levels were significantly higher in 
shLGALS3 HT-29 cells compared to scramble shRNA-transfected cells (Fig. 6B).
Early control of host innate responses to bacterial infections is primarily dependent on macrophages, which 
function as the first line of host defense against a pathogen34. Therefore, we next sought to characterize the dif-
ferential role of Gal-3 in NLRP3- or NLRC4-induced caspase-1 activation in macrophages using BMDMs from 
WT and Lgal3−/− C57BL/6 mice. After BMDMs were treated with LPS plus adenosine triphosphate (ATP) or 
nigericin, a well described NLRP3 inflammasome stimulator, there was no significant difference in caspase-1 
activation or IL-1β production (Fig. 7A and Supplemenatry Fig. 8A,B). However, infection with Salmonella 
Figure 7. Loss of galectin-3 increases NLRC4 inflammasomes in macrophages. (A) Bone marrow-derived 
macrophages (BMDMs) were left untreated or treated with LPS, ATP, or nigericin. Cultural supernatants 
or soluble lysates were immunoblotted with anti-caspase 1. IL-1β levels in culture media were measured by 
enzyme-linked immunosorbent assay (ELISA). (B) BMDMs were infected with S. typhimurium. Supernatants 
or lysates were immunoblotted with the appropriate antibodies, as indicated. IL-1β levels in the culture media 
were measured by ELISA. (C) mRNA levels of Nlrc4 in the colon tissues of wild-type (WT) and galectin-3 
(Gal-3) knock-out (KO) mice were quantified by real-time quantitative reverse transcription polymerase chain 
reaction and normalized to β-actin. Unt, untreated; LPS treated with lipopolysaccharide; ATP, ATP-treated; 
Niger, nigericin-treated; Procasp-1, procaspase 1; p20, cleaved caspase 1; Pro-IL-1β, pro-interleukin 1 beta. 
*p < 0.05 vs. WT, ***p < 0.001 vs. untreated or WT.
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typhimurium, activator of the NLRC4 inflammasome, led to caspase-1 activation and increased IL-1β production 
in BMDMs from Lgal3−/− mice (Fig. 7B and Supplementary Fig. 8C–G). Importantly, NLRC4 mRNA levels were 
higher in Lgal3−/− BMDMs than in WT BMDMs (Fig. 7C). These results suggest that Gal-3 may act as a negative 
regulator of NLRC4, but not NLRP3.
Discussion
In the present study, we utilized a proteomics approach to identify a distinct protein profile in intestinal tissues 
from intestinal BD patients. Among other differential protein levels, we observed significantly lower Gal-3 lev-
els in intestinal BD colon tissues, an interesting observation given that Gal-3 has been reported as an immune 
response regulator in other chronic inflammatory disorders, including IBD. Using patient tissues, HT-29 cells, 
and murine BMDMs, we demonstrated that Gal-3 modulates ER stress, autophagy, and inflammasome activation, 
which suggests that the Gal-3 protein may play a protective role against intestinal BD. To the best of our knowl-
edge, this is the first study to identify and characterize a biomarker of intestinal BD using a proteomics approach.
IBD is thought to be caused by an inappropriate and continuing inflammatory response to commensal microbes 
and epithelial barrier defects in a genetically susceptible host. To date, GWAS successfully identified genetic loci that 
contribute to IBD pathogenesis, including genes encoding barrier function proteins (GNA12 and HNF4A), innate 
and adaptive immune regulatory proteins (NOD2, CARD9, IL23R, and TNFSF15), autophagy proteins (ATG16L1, 
IRGM, and LRRK2), and ER stress proteins (XBP1)10,11,21. However, studies in the context of IBD have shown that 
genetic changes do not always translate directly into protein activity, and importantly, genomics does not consider 
posttranslational modifications. Therefore, in recent decades, proteomics approaches have proven a complementary 
method to genomics for biomarker discovery in IBD14–16. Some markers have been revealed that differentiate IBD 
subtypes (serum antibody anti-Saccharomyces cerevisiae antibody; ASCA, perinuclear anti-neutrophil cytoplasmic 
antibody; pANCA)35,36, while others predict relapse (fecal calprotectin)23. Similar to IBD, intestinal BD is known 
Figure 8. A model for galectin-3-mediated regulation of autophagy, endoplasmic reticulum (ER) stress, and 
inflammasomes in epithelial cells. Down-regulation of galectin-3 led to epithelial cell death due to unresolved 
ER stress and autophagy defects, resulting in activation of NLRC4 inflammasomes in response to autophagy 
defects.
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to have a wax-and-wane disease course and frequent relapse, even with surgery5; however, data regarding disease 
pathogenesis are extremely limited. Because we recently reported that genetic variants in IL17A, IL23R, STAT4, 
NAALADL2, and YIPF7 are associated with intestinal BD pathogenesis12,13, in this study, we aimed to investigate 
differentially expressed proteins of intestinal BD using a proteomics approach.
We initially identified seven highly differential protein spots in colonic tissues from intestinal BD patients, 
including proteins identified as heat shock proteins, proteins involved in oxidative stress, and inflammatory pro-
teins23–25. Among them, in particular, we observed significantly lower levels of Gal-3 in inflamed colonic tissues 
from intestinal BD patients, which is in line with prior studies reporting reduced levels of the Gal-3 protein in 
inflamed IBD tissues20,37,38. We therefore hypothesized that Gal-3 plays a protective role in intestinal BD and 
sought to further elucidate the underlying mechanisms of Gal-3 in intestinal immune responses in inflammatory 
bowel conditions.
Gal-3, a 31-kDa chimeric lectin, is a member of a large family of S-type lectins characterized by binding 
affinity for β-galactose-containing carbohydrates. Gal-3, which can be found both intra- and extra-cellularly, 
is expressed by various cell types, including epithelial cells in the gastrointestinal tract and activated immune 
cells39–41. By binding to its glycan ligand at the cell surface, Gal-3 regulates inflammatory responses by influencing 
cytokine secretion, cell adhesion and migration, and apoptosis, and additionally controls immune responses 
by regulating damage-associated molecular patterns and pathogen-associated molecular pattern pathways39–41. 
Although Gal-3 is thought to play a critical role in the modulation of chronic inflammatory disorders such as IBD 
and other autoimmune diseases26–28,42, findings have been contradictory. For example, several studies suggest that 
Gal-3 negatively regulates inflammatory responses that diminish interaction between Gal-3 and laminin, poten-
tially causing increased intestinal permeability38 and Gal-3 downregulation may result in inappropriate T cell 
proliferation37. In contrast, other studies have reported a pro-inflammatory role of Gal-3 that may increase cell 
survival43 and promote activation of the NLRP3 inflammasome in macrophages42. Our current findings strongly 
support a protective role of Gal-3 against the development of intestinal inflammation. Further studies comparing 
the expression levels of Gal-3 between intestinal BD and IBD tissues could clarify the distinctive pathogenic role 
of Gal-3 in intestinal BD.
Barrier integrity is important to maintain immune tolerance towards intestinal microbiota and prevent 
chronic intestinal inflammation7,9. Upon ER stress either by genetic or environmental factors, GRP78 senses 
misfolded proteins in the stressed ER and activates three distinct unfolded protein response (UPR) signaling 
pathways to reduce ER stress and induce autophagy44,45. In addition, both UPR (XBP1 and AGR2) and auto-
phagy (ATG16L1, IRGM, and LRRK2)-related genes have been associated with IBD10,11 and several studies have 
shown evidence for increased ER stress in the small intestine of CD patients46. Similarly, we demonstrate here 
that reduced levels of the Gal-3 protein in HT-29 cells were associated not only with increased GRP78 expression 
and XBP1 splicing, but also with increased LPS or serum starvation-induced cell death. These findings suggest 
that unresolved ER stress in Gal-3 knockdown intestinal epithelial cells might lead to increased apoptosis which 
ultimately disrupts epithelial barrier integrity.
Autophagy, a mechanism for the resolution of ER stress, is activated in response to multiple stresses including 
hypoxia, infection, and nutritional starvation. Thus, UPR inevitably engages autophagy to compensate for ER 
stress in the intestinal epithelia9,45. Because it was reported that Gal-3 might be used as a marker of damaged 
endomembranes31 and Gal-3 on damaged lysosome can be targeted by autophagy47,48, we evaluated whether 
loss of Gal-3 affected autophagic clearance in an ER stress condition. We noted that Gal-3 knockdown epithe-
lial cells had fewer intact lysosomes compared to control cells, showing more ruptured or aberrant lysosomes. 
Accompanying LC3B accumulation, in turn, might be caused by impaired degradation of autophagosomes due to 
an autophagy defect, as shown in a previous study49. In addition, Gal-3 was colocalized with lysosomes, and not 
autophagosomes. Upon binding to its ligand, non-lectin domains of Gal-3 interact with one another and lead to 
oligomerization in lattices, which may serve as a platform for assembly of other proteins and the occurrence of 
signaling31. The lysed membrane labeled by Gal-3 indeed recruits autophagy markers and is degraded by auto-
phagic pathways48. All these data indicate that uncompensated ER stress and autophagy defects in intestinal epi-
thelial cells lacking Gal-3 promote intestinal inflammation and lead to cell death in inflammatory conditions44,45, 
exacerbating colitis29,30. Nevertheless, further studies are needed to establish a direct link between Gal-3, ER 
stress, autophagy, and the development of intestinal BD.
Autophagy also negatively regulates inflammasome activity by degrading and removing assembled inflam-
masomes, by removing damaged mitochondria that would otherwise promote inflammasome activation, and by 
downregulating pro-IL-1β32. We observed increased levels of caspase-1 activation, IL-1β production, and NLRC4 
inflammasome activation in Lgals3‒/‒ BMDMs, consistent with a previous report that ATG16L1-deficient cells 
have enhanced inflammasome activation in response to TLR stimulation50. Our results suggest that autophagy 
defects in response to bacterial triggers in turn leave inflammasome activation unchecked and hyperactive.
It is intriguing that we observed a distinct effect of Gal-3 on the regulation of inflammasomes, in that Gal-3 
appears to regulate NLRC4, but not NLRP3 inflammasomes. Previous studies have demonstrated that intestinal 
phagocytic cells can detect invading pathogenic bacteria by the NLRC4 inflammasome and trigger inflammatory 
responses33,51. Because the role of inflammasomes in colitis is not yet fully understood, further studies are needed 
to clarify the role of Gal-3-regulated inflammasomes in intestinal BD pathogenesis.
We additionally observed decreased IL-10 levels in HT-29 cells transfected with shLGALS3. Consistent with 
this observation, reduced IL-10 expression in response to Gal-3 downregulation has been observed in dendritic 
cells52, further supporting a role for Gal-3 in downregulating immune responses that may incite intestinal inflam-
mation. Because it has been also demonstrated that the disruption of IL-10 causes a loss of suppression of the 
mucosal immune response and even excessive apoptosis and necrosis53, loss of IL-10 in cells with reduced Gal-3 
expression may aggravate intestinal inflammation and cell death. However, our results were not reproduced with 
rhGal-3 administration. Several studies have suggested a different role for Gal-3 depending on various factors 
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such as target cells and specific inflammatory conditions39 implicating the need for further investigation into the 
regulation of T-cell function by Gal-3.
Here we describe for the first time a novel pathway by which Gal-3 down-regulation may play a protective 
role in the development of intestinal BD via ER stress, autophagy defects, and NLRC4 inflammasome activation 
(Fig. 8), suggesting new insights of Gal-3 in the intestinal BD disease pathogenesis. Further large-scale stud-
ies are warranted to confirm our findings. In addition, our data need to be replicated in a colitis model spe-
cific for intestinal BD. BD-like mouse model produced by herpes simplex virus inoculation showed BD-like 
symptoms including skin manifestations, eye symptoms, orogenital ulcers, and gastrointestinal ulcer (5.2%)54. 
Unfortunately, however, there are currently no specific animal models for intestinal BD. By unravelling the path-
ogenic mechanisms of intestinal BD, the diagnosis of intestinal BD is likely to be improved, leading to faster and 
more appropriate treatments for patients, ultimately increasing their quality of life.
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